ISMRM21 - MRI Advances Within the Co-Clinical Cancer Trials Network: Informing Cancer Clinical Trials Through Preclinical Imaging

MRI Advances Within the Co-Clinical Cancer Trials Network: Informing Cancer Clinical Trials Through Preclinical Imaging

Member-Initiated Symposium

Monday, 17 May 2021

Concurrent 8

17:00 - 17:30

Moderators: Joseph Ackerman & Rong Zhou

Session Number: MIS-16

Parent Session: MRI Advances Within the Co-Clinical Cancer Trials Network: Informing Cancer Clinical Trials Through Preclinical Imaging

Session Number:MIS-16

Organizers
Joseph Ackerman, Rong Zhou

Overview
This symposium was organized with the assistance of teams from the NCI Co-Clinical Imaging Research Program (CIRP) Network. The session will: (1) describe the unique technical challenges to achieving quantitative MRI (qMRI) biomarkers with small-animal models of cancer; (2) provide innovative solutions to address these challenges; and (3) show how preclinical qMRI findings can inform clinical cancer imaging trials. The initial presentation (20 min) will define challenges and potential solutions unique to preclinical qMRI. This will be followed by theme-specific presentations regarding six new qMRI advances (4 @ 1x15-minute, single-speaker; 2 @ 2x8-minute, dual-speaker): (1) achieving ultrahigh spatial resolution for murine tibia bone marrow imaging; (2) mitigating respiratory motion artifacts in DWI of mouse abdomen; (3) increasing rigor and reproducibility in hyperpolarized 13C metabolic MR; (4) leveraging complementary PET/MRI findings; (5) validating biomarkers using multimodal imaging; (6) predicting tumor growth and response by imaging-driven mechanistic models. A brief concluding presentation (8 min) will describe the CIRP initiative. Motivated by the increasing use of preclinical qMRI in translational cancer research, this session will complement and enhance the preclinical imaging offerings of the annual meeting. It will provide a timely perspective on the unique experimental challenges posed by small-animal MRI and on the technical innovations that provide solutions.

Target Audience
Researchers engaged in quantitative small-animal MRI and entrepreneurs aiming to enhance preclinical MRI capability by hard/software innovations.

Educational Objectives
As a result of attending this course, participants should be able to:
Upon completion of this course, participants should be able to: - Explain the unique challenges to preclinical qMRI posed by small-animal models; - Describe innovative solutions to these challenges, leading to improvements in resolution, motion mitigation, rigor, and repeatability; - Appraise the value of integrating qMRI biomarkers with other data platforms for cancer research; and - Learn about an opportunity to join the NCI CIRP Network as a grantee or an associate member.

			Solving Fundamental Challenges in Preclinical MRI to Improve Cancer Clinical Trials Thomas Yankeelov University of Texas at Austin
			MR Imaging of Mice Tibia for Co-Clinical Studies of Myelofibrosis Ghoncheh Amouzandeh University of Michigan
			Improving Murine Abdominal DWI by Radial k-Space Sampling & Deep Learning Yong Fan¹, Steven Pickup² University of Pennsylvania¹, University of Pennsylvania²
			Increased Rigor & Reproducibility in Hyperpolarized 13C with Mouse Cancer Models Renuka Sriram University of California, San Francisco
			Promises, Challenges & Real-World Experience with PET/MR Imaging of Small-Animal Models in Co-Clinical Cancer Research Charles Manning¹, Kooresh Shoghi² The University of Texas MD Anderson Cancer Center¹, Washington University in St. Louis²
			Advances in Validation of Imaging Markers: Connecting 3D Multi-Modal MR Imaging & 2D Pathology in a Mouse Model of Sarcoma Stephanie Blocker Duke University
			Predicting Therapeutic Response via Quantitative MRI Anum Kazerouni University of Washington
			The NCI Co-Clinical Imaging Research Resource Program (CIRP) Huiming Zhang National Cancer Institute